CORPORATE

Launched by Borsa Italiana, ELITE is targeted to companies aiming at strengthening their global leadership

The company’s efforts try to grant African patients better access to treatments

The MIT Technology Review Italia’s award given in Bologna in mid-May

The bonds have been placed with leading international institutional investors and will be listed on the Irish Stock Exchange

Achieved results of 425 million euros turnover and a 25% profitability

500,000 IU of Factor IX shipped to the Pakistan Hemophilia Patients Welfare Society Rawalpindi.

The aim is to broaden access to haemophilia treatment regardless of the patients’ geographical location.

Kedrion announces that, effective 1st July, 2013, Grifols S.A. will complete the transfer to Kedrion of all the operations for managing the plasma fractionation plant of Melville, State of New York (USA), owned by Kedrion. This action is part of the agreements entered into in 2011, included in the Consent Agreement of the Federal Trade

Kedrion reinforces its presence in the United States. The company, based in Castelvecchio Pascoli (Lucca), acquired from Ortho-Clinical Diagnostics, Inc. (OCD) the branch specialising in the production of human anti-D immunoglobulin, an effective product for the prevention of the “haemolytic disease of the newborn” (HDN), a condition that occurs in Rh-positive foetuses and new-born babies

Fondo Strategico Italiano (FSI), the Italian Strategic Fund, has become a joint owner of Kedrion with an overall financial contribution of 150 million euros (75 million euros in capital increase and 75 million euros in a convertible or reimbursable line of credit). The company’s ownership will be divided as follows: 48.8 per cent to the